Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028 (NASDAQ:STOK)

Stoke Therapeutics (STOK) Q2 2026 earnings call: EMPEROR enrollment done, rolling NDA in Q1 2027, Q3 2027 readout, cash runway—read now.

Stoke outlines rolling NDA in Q1 2027 as $420M cash supports potential U.S. launch by early 2028 (NASDAQ:STOK) | Seeking Alpha

Earnings Call Insights: Stoke Therapeutics (STOK) Q2 2026

Management view

"Starting with our Phase III EMPEROR study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevunersen" (CEO & Director Ian Smith). "We continue our

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Entering text into the input field will update the search result below

Quick Insights

What are the investment implications of EMPEROR Phase III enrollment and timeline for Stoke Therapeutics?

EMPEROR enrollment is complete with 162 patients and no discontinuations, positioning the Phase III readout for Q3 2027 and enabling a rolling NDA submission starting Q1 2027, which supports Stoke's potential early-2028 U.S. launch ambitions.

How does Stoke Therapeutics’ pro forma cash position support operations and upcoming milestones?

Stoke reports a pro forma cash position of approximately $420 million, which together with anticipated reimbursements and milestone payments, is expected to fund operations through a potential U.S. commercial launch in early 2028.

What regulatory and commercialization risks could affect Stoke Therapeutics’ approval and launch of zorevunersen?

Key risks include how secondary endpoints are handled in regulatory filings with the FDA and capacity/readiness of institutions to deliver intrathecal therapies, with ongoing work required to ensure site qualification for a successful launch.

Recommended For You

More

Trending News

See More

»